GlassScriptPhysician profile
Clifford L Weldon
NPI 1528194545
$4,224.03
in general payments reported to CMS, 2019-2025
26 companies · $705 in 2025
The $705 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $154 · 2021: $595 · 2022: $929 · 2023: $766 · 2024: $954 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $809.81 | 2021-2025 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $549.26 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $471.15 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $366.40 | 2021-2023 | Xarelto |
| Abiomed | $308.63 | 2019-2025 | Impella |
| Pfizer INC. | $244.05 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.38 | 2022-2025 | Jardiance |
| Esperion Therapeutics, INC. | $206.67 | 2022-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.53 | 2022-2025 | Lifevest |
| Amgen INC. | $120.04 | 2020-2025 | Repatha, Repatha |
| Novo Nordisk INC | $98.89 | 2024-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $98.53 | 2021-2024 | Brilinta, Farxiga |
| Actelion Pharmaceuticals US, INC. | $83.09 | 2021-2024 | Opsumit |
| Boston Scientific Corporation | $75.41 | 2022-2024 | Mylux Patient Kit With Mobile Device, Resonate El Icd Vr |
| Kiniksa Pharmaceuticals International, Plc | $70.66 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $49.66 | 2023-2024 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $49.57 | 2022-2023 | |
| Chiesi USA, INC. | $44.89 | 2022 | |
| Amarin Pharma, INC. | $39.53 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.35 | 2023-2025 | |
| Angiodynamics, INC. | $26.32 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.88 | 2022 | |
| Vital Connect, INC | $21.68 | 2024 | Vitalpatch Rtm |
| Edwards Lifesciences Corporation | $21.44 | 2021 | |
| Lilly USA, LLC | $15.15 | 2025 | Zepbound, Mounjaro |
| Bardy Diagnostics, INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Weldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.